Prentice E D, Rayburn W F
University of Nebraska Medical Center, Omaha 68198-6810.
Clin Obstet Gynecol. 1991 Jun;34(2):360-8. doi: 10.1097/00003081-199106000-00018.
Fetal drug therapies have emerged as a promising avenue for the prevention or correction of disease during fetal or immediate postnatal life. Despite slow progress, several medications have been developed for in utero therapy of disorders which relate to fetal and neonatal pulmonary, cardiac, neurologic, and growth disorders. However, ethical and regulatory constraints require protection of the mother and fetus while causing no more than necessary additional risk. Appreciating these constraints will lead to the identification of pragmatic questions which should be answered before evaluating the efficacy and safety of a particular treatment or research proposal.
胎儿药物治疗已成为预防或纠正胎儿期或出生后即刻疾病的一条有前景的途径。尽管进展缓慢，但已经研发出了几种药物用于子宫内治疗与胎儿和新生儿肺部、心脏、神经以及生长紊乱相关的疾病。然而，伦理和监管方面的限制要求在不造成不必要额外风险的前提下保护母亲和胎儿。认识到这些限制将有助于识别一些务实的问题，在评估特定治疗方法或研究提议的疗效和安全性之前应对这些问题进行解答。
